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Background
Congenital CMV infection is a major cause of disability in
newborns. An effective preconception vaccine is a major
public health priority. The guinea-pig cytomegalovirus
(GPCMV) model was utilized to evaluate the efficacy of
live, attenuated CMV vaccines generated using a bacterial
artificial chromosome (BAC) approach.

29 live and 22 dead pups (43% mortality, mean pup
weight of 89 g), compared to 45 live and 14 dead pups
born to 15 litters in the vaccine group (26% mortality,
mean pup weight 106 g; p<0.05 vs. control). The two vaccines were comparable in reducing GPCMV transmission
at the placental and fetal levels.

Conclusions
Methods
The GPCMV genome was cloned as a BACmid in E. coli
and used to regenerate a wild-type viral vaccine (wt), and
a highly attenuated recombinant vaccine deleted of the
gene encoding the dominant T-cell target, UL83 (pp65).
Seronegative animals were immunized with a two-dose
series of each vaccine (0- and 3- week schedule), or placebo. Following establishment of pregnancy, dams were
challenged with salivary gland-passaged (SG) GPCMV
(5×105 pfu) in the second trimester, and pregnancy outcomes were compared.

Live, attenuated CMV vaccines are effective at preventing
congenital infection and disease in the guinea pig model.
Of interest, although UL83 is an effective subunit vaccine
in guinea-pigs, immune responses to UL83 are not essential for fetal protection in the context of a live-virus vaccine. Recombinant CMV vaccines with targeted mutations
of pathogenesis or immune evasion genes warrant further
consideration in clinical trials.

Results
Vaccinated dams seroconverted to GPCMV antigen. ELISA
titers were significantly higher in the wt (2.8+/−0.3 log10)
compared to the 409 group (2.5+/−0.2 log10; p<0.05).
Vaccination resulted in highly significant reductions in
the magnitude and duration of DNAemia post-SG challenge, and was associated with improved pregnancy outcomes. Among 13 litters in the control group, there were
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